251 results on '"Kolb, Brigitte"'
Search Results
2. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study
- Author
-
Roussel, Murielle, Lauwers-Cances, Valérie, Macro, Margaret, Leleu, Xavier, Royer, Bruno, Hulin, Cyrille, Karlin, Lionel, Perrot, Aurore, Touzeau, Cyrille, Chrétien, Marie-Lorraine, Rigaudeau, Sophie, Dib, Mamoun, Nicolas-Virelizier, Emmanuelle, Escoffre-Barbe, Martine, Belhadj, Karim, Mariette, Clara, Stoppa, Anne-Marie, Araujo, Carla, Doyen, Chantal, Fontan, Jean, Kolb, Brigitte, Garderet, Laurent, Brechignac, Sabine, Malfuson, Jean-Valère, Jaccard, Arnaud, Lenain, Pascal, Borel, Cécile, Hebraud, Benjamin, Benbrahim, Omar, Dorvaux, Véronique, Manier, Salomon, Augeul-Meunier, Karine, Vekemans, Marie-Christiane, Randriamalala, Edouard, Chaoui, Driss, Caers, Jo, Chaleteix, Carine, Benboubker, Lofti, Vincent, Laure, Glaisner, Sylvie, Zunic, Patricia, Slama, Borhane, Eveillard, Jean-Richard, Humbrecht-Kraut, Catherine, Morel, Véronique, Mineur, Philippe, Eisenmann, Jean-Claude, Demarquette, Hélène, Richez, Valentine, Vignon, Marguerite, Caillot, Denis, Facon, Thierry, Moreau, Philippe, Colin, Anne-Laurène, Olivier, Pascale, Wuilleme, Soraya, Avet-Loiseau, Hervé, Corre, Jill, and Attal, Michel
- Published
- 2022
- Full Text
- View/download PDF
3. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
- Author
-
Perrot, Aurore, Lauwers-Cances, Valerie, Corre, Jill, Robillard, Nelly, Hulin, Cyrille, Chretien, Marie-Lorraine, Dejoie, Thomas, Maheo, Sabrina, Stoppa, Anne-Marie, Pegourie, Brigitte, Karlin, Lionel, Garderet, Laurent, Arnulf, Bertrand, Doyen, Chantal, Meuleman, Nathalie, Royer, Bruno, Eveillard, Jean-Richard, Benboubker, Lotfi, Dib, Mamoun, Decaux, Olivier, Jaccard, Arnaud, Belhadj, Karim, Brechignac, Sabine, Kolb, Brigitte, Fohrer, Cecile, Mohty, Mohamad, Macro, Margaret, Richardson, Paul G., Carlton, Victoria, Moorhead, Martin, Willis, Tom, Faham, Malek, Anderson, Kenneth C., Harousseau, Jean-Luc, Leleu, Xavier, Facon, Thierry, Moreau, Philippe, Attal, Michel, Avet-Loiseau, Hervé, and Munshi, Nikhil
- Published
- 2018
- Full Text
- View/download PDF
4. Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma
- Author
-
Pertesi, Maroulio, Vallée, Maxime, Wei, Xiaomu, Revuelta, Maria V., Galia, Perrine, Demangel, Delphine, Oliver, Javier, Foll, Matthieu, Chen, Siwei, Perrial, Emeline, Garderet, Laurent, Corre, Jill, Leleu, Xavier, Boyle, Eileen M., Decaux, Olivier, Rodon, Philippe, Kolb, Brigitte, Slama, Borhane, Mineur, Philippe, Voog, Eric, Le Bris, Catherine, Fontan, Jean, Maigre, Michel, Beaumont, Marie, Azais, Isabelle, Sobol, Hagay, Vignon, Marguerite, Royer, Bruno, Perrot, Aurore, Fuzibet, Jean-Gabriel, Dorvaux, Véronique, Anglaret, Bruno, Cony-Makhoul, Pascale, Berthou, Christian, Desquesnes, Florence, Pegourie, Brigitte, Leyvraz, Serge, Mosser, Laurent, Frenkiel, Nicole, Augeul-Meunier, Karine, Leduc, Isabelle, Leyronnas, Cécile, Voillat, Laurent, Casassus, Philippe, Mathiot, Claire, Cheron, Nathalie, Paubelle, Etienne, Moreau, Philippe, Bignon, Yves–Jean, Joly, Bertrand, Bourquard, Pascal, Caillot, Denis, Naman, Hervé, Rigaudeau, Sophie, Marit, Gérald, Macro, Margaret, Lambrecht, Isabelle, Cliquennois, Manuel, Vincent, Laure, Helias, Philippe, Avet-Loiseau, Hervé, Moreno, Victor, Reis, Rui Manuel, Varkonyi, Judit, Kruszewski, Marcin, Vangsted, Annette Juul, Jurczyszyn, Artur, Zaucha, Jan Maciej, Sainz, Juan, Krawczyk-Kulis, Malgorzata, Wątek, Marzena, Pelosini, Matteo, Iskierka-Jażdżewska, Elzbieta, Grząśko, Norbert, Martinez-Lopez, Joaquin, Jerez, Andrés, Campa, Daniele, Buda, Gabriele, Lesueur, Fabienne, Dudziński, Marek, García-Sanz, Ramón, Nagler, Arnon, Rymko, Marcin, Jamroziak, Krzysztof, Butrym, Aleksandra, Canzian, Federico, Obazee, Ofure, Nilsson, Björn, Klein, Robert J., Lipkin, Steven M., McKay, James D., and Dumontet, Charles
- Published
- 2019
- Full Text
- View/download PDF
5. Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma
- Author
-
Fouquet, Guillemette, Karlin, Lionel, Macro, Margaret, Caillot, Denis, Roussel, Murielle, Arnulf, Bertrand, Pegourie, Brigitte, Petillon, Marie Odile, Mathiot, Claire, Hulin, Cyrille, Kolb, Brigitte, Stoppa, Anne-Marie, Brechiniac, Sabine, Rodon, Philippe, Dib, Mamoun, Tiab, Mourad, Richez, Valentine, Araujo, Carla, Wetterwald, Marc, Garderet, Laurent, Royer, Bruno, Perrot, Aurore, Benboubker, Lotfi, Decaux, Olivier, Escoffre-Barbe, Martine, Fermand, Jean Paul, Moreau, Philippe, Avet-Loiseau, Hervé, Attal, Michel, Facon, Thierry, and Leleu, Xavier
- Published
- 2018
- Full Text
- View/download PDF
6. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial
- Author
-
Moreau, Philippe, Hulin, Cyrille, Macro, Margaret, Caillot, Denis, Chaleteix, Carine, Roussel, Murielle, Garderet, Laurent, Royer, Bruno, Brechignac, Sabine, Tiab, Mourad, Puyade, Mathieu, Escoffre, Martine, Stoppa, Anne-Marie, Facon, Thierry, Pegourie, Brigitte, Chaoui, Driss, Jaccard, Arnaud, Slama, Borhane, Marit, Gerald, Laribi, Karim, Godmer, Pascal, Luycx, Odile, Eisenmann, Jean-Claude, Allangba, Olivier, Dib, Mamoun, Araujo, Carla, Fontan, Jean, Belhadj, Karim, Wetterwald, Marc, Dorvaux, Véronique, Fermand, Jean-Paul, Rodon, Philippe, Kolb, Brigitte, Glaisner, Sylvie, Malfuson, Jean-Valere, Lenain, Pascal, Biron, Laetitia, Planche, Lucie, Caillon, Helene, Avet-Loiseau, Herve, Dejoie, Thomas, and Attal, Michel
- Published
- 2016
- Full Text
- View/download PDF
7. Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma
- Author
-
Moreau, Philippe, Kolb, Brigitte, Attal, Michel, Caillot, Denis, Benboubker, Lotfi, Tiab, Mourad, Touzeau, Cyrille, Leleu, Xavier, Roussel, Murielle, Chaleteix, Carine, Planche, Lucie, Chiffoleau, Anne, Fortin, June, Avet-Loiseau, Hervé, Mary, Jean-Yves, Hulin, Cyrille, and Facon, Thierry
- Published
- 2015
- Full Text
- View/download PDF
8. Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results
- Author
-
Leleu, Xavier, Karlin, Lionel, Macro, Margaret, Hulin, Cyrille, Garderet, Laurent, Roussel, Murielle, Arnulf, Bertrand, Pegourie, Brigitte, Kolb, Brigitte, Stoppa, Anne Marie, Brechiniac, Sabine, Marit, Gerald, Thielemans, Beatrice, Onraed, Brigitte, Mathiot, Claire, Banos, Anne, Lacotte, Laurence, Tiab, Mourad, Dib, Mamoun, Fuzibet, Jean-Gabriel, Petillon, Marie Odile, Rodon, Philippe, Wetterwald, Marc, Royer, Bruno, Legros, Laurence, Benboubker, Lotfi, Decaux, Olivier, Escoffre-Barbe, Martine, Caillot, Denis, Fermand, Jean Paul, Moreau, Philippe, Attal, Michel, Avet-Loiseau, Herve, and Facon, Thierry
- Published
- 2015
- Full Text
- View/download PDF
9. Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial
- Author
-
Cambau, Emmanuelle, Durand-Zaleski, Isabelle, Bretagne, Stéphane, Brun-Buisson, Christian, Cordonnier, Catherine, Duval, Xavier, Herwegh, Stéphanie, Pottecher, Julien, Courcol, René, Bastuji-Garin, Sylvie, Lefort, Agnès, Mantz, Jean, Pease, Sébastien, Lavagna, Leïla, Nicolas-Chanoine, Marie Hélène, Leflon, Véronique, Marcon, Estelle, Ruimy, Raymond, Andremont, Antoine, Lebras, Jacques, Iung, Bernard, Regnier, Bernard, Yeni, Patrick, Montravers, Philippe, Mourvillier, Bruno, Ilic-Habensus, Emila, Talbi, Nadia El Alami, Lasocki, Sigismond, Bouscary, Didier, Mira, Jean-Paul, Grimaldi, David, Marin, Nathalie, Doloy, Alexandra, Poyart, Claire, Scherrer, Emmanuel, Chambon-Pautas, Cecile, Cook, Fabrice, Mekontso-Dessap, Armand, Schortgen, Frédérique, Chedevergne, Karine, Vernant, Jean-Paul, Gauvin-Bodin, Liliane, Trouillet, Jean-Louis, Chastre, Jean, Bricaire, François, Brossier, Florence, Jarlier, Vincent, Dheder, Nathalie, Nieszkowska, Ania, Datry, Annick, Fekkar, Arnaud, Buffet, Pierre, Mazier, Rommy, Brun, Sophie, Meyssonnier, Vanina, Isnard, Françoise, Baudel, Jean-Luc, Meynard, Jean-Luc, Petit, Jean-Claude, Lalande, Valérie, Roux, Patricia, Raffoux, Emmanuel, Ribaud, Patricia, Das, Vincent, Schlemmer, Benoit, Azoulay, Elie, Chimot, Loic, Molina, Jean-Michel, Ponscarme, Diane, Pavie, Juliette, Simon, François, Casin, Isabelle, Menotti, Jean, Gruson, Didier, Bessède, Emilie, Guilhon, Emmanuelle, Accoceberry, Isabelle, Millet, Pascal, Bébéar, Cécile, Berthoux, Christian, Tonnelier, Jean-Marie, Garre, Michel, Hery-Arnaud, Geneviève, Payan, Christopher, Nevez, Gilles, Timsit, Jean-Francois, Cahn, Jean-Yves, Brion, Jean-Paul, Le beau, Bernard, Courby, Stephane, Pelloux, Hervé, Maurin, Max, Epaulard, Olivier, Hamidfar, Rebecca, Berthon, Céline, Coiteux, Valérie, Terriou, Louis, Nseir, Saadalla, Auffray, Jean-Luc, Jouet, Jean-Pierre, Durocher, Alain, Faure, Karine, Clavel, Marc, Camus, Daniel, Dugard, Anthony, Tisseuil, Chantal, Duchiron, Cécile, Ajzenberg, Daniel, Bordessoule, Dominique, Garnier, Fabien, François, Bruno, Ploy, Marie-Cécile, Darde, Marie-Laure, Chaury, Marie-Pierre, Giraud, Stephane, Jaccard, Arnaud, Moreau, Stéphane, Réménieras, Liliane, Touati, Mohamed, Turlure, Pascal, Amiel, Jean-Bernard, Pichon, Nicolas, Postil, Déborah, Vignon, Philippe, Espinouse, Daniel, Jacques, Didier, De Monbrison, Frédérique, Grozel, Jean-Michel, Chomarat, Monique, Gueugniaud, Pierre-Yves, Sanogo, Rokiatou, Drancourt, Michel, Fournier, Pierre Edouard, Roux, Véronique, Delmer, Alain, Himberlin, Chantal, Kolb, Brigitte, Lé, Quoc Hung, Appriou, Morgane, Cousson, Joël, Nazeyrollas, Pierre, Strady, Christophe, Dechamps, Christophe, Vernet, Véronique, Delmer, Alain, Toubas, Dominique, Guyotat, Denis, Auboyer, Christian, Zeni, Fabrice, Alamartine, Eric, Cathebras, Pascal, Lucht, Frédéric, Viallon, Alain, Melis, Adrien, Ros, Alain, Carricajo, Anne, Devanlay, Camille, Labruyere, Carine, Vautrin, Catherine, Cazorla, Céline, Tavernier, Emmanuelle, Grattard, Florence, Aubert, Gérald, Morel, Jerome, Cornillon, Jérome, Abba, Karima, Flori, Pierre, Sung, Roger Tran Manh, Pozzetto, Bruno, Schneider, Francis, Hansmann, Yves, Herbrecht, Raoul, Jaulhac, Benoit, Piémont, Yves, Lestcher, Valérie, Colombat, Philippe, Senecal, Delphine, Garot, Denis, Perrottin, Dominique, Besnier, Jean-Marc, Goudeau, Alain, Lanotte, Philippe, Chandenier, Jacques, Baloul, Samia, Corbel, Céline, Dabbech, Moufida, Gaba, Mabel, Jozefowicz, Elsa, Lafaye, Magali, Maugard, Fabien, Rabeuf, Remi, Rabetrano, Hasina, Veerabudun, Kalaivani, Viallette, Cédric, Stahl, Jean-Paul, Delhaes, Laurence, and The EVAMICA study team
- Published
- 2017
- Full Text
- View/download PDF
10. Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical Trial
- Author
-
Bridoux, Frank, Carron, Pierre-Louis, Pegourie, Brigitte, Alamartine, Eric, Augeul-Meunier, Karine, Karras, Alexandre, Joly, Bertrand, Peraldi, Marie-Noëlle, Arnulf, Bertrand, Vigneau, Cécile, Lamy, Thierry, Wynckel, Alain, Kolb, Brigitte, Royer, Bruno, Rabot, Nolwenn, Benboubker, Lotfi, Combe, Christian, Jaccard, Arnaud, Moulin, Bruno, Knebelmann, Bertrand, Chevret, Sylvie, and Fermand, Jean-Paul
- Published
- 2017
- Full Text
- View/download PDF
11. Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study
- Author
-
Hulin, Cyrille, Offner, Fritz, Moreau, Philippe, Roussel, Murielle, Belhadj, Karim, Benboubker, Lotfi, Caillot, Denis, Facon, Thierry, Garderet, Laurent, Kuhnowski, Frédérique, Stoppa, Anne-Marie, Kolb, Brigitte, Tiab, Mourad, Jie, Kon-Siong, Westerman, Matthijs, Lambert, Jérôme, Pei, Lixia, Vanquickelberghe, Veronique, de Boer, Carla, Vermeulen, Jessica, Kampfenkel, Tobias, Sonneveld, Pieter, and van de Donk, Niels W.C.J.
- Subjects
Letters to the Editor - Published
- 2021
12. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02
- Author
-
Leleu, Xavier, Attal, Michel, Arnulf, Bertrand, Moreau, Philippe, Traulle, Catherine, Marit, Gerald, Mathiot, Claire, Petillon, Marie Odile, Macro, Margaret, Roussel, Murielle, Pegourie, Brigitte, Kolb, Brigitte, Stoppa, Anne Marie, Hennache, Bernadette, Bréchignac, Sabine, Meuleman, Nathalie, Thielemans, Beatrice, Garderet, Laurent, Royer, Bruno, Hulin, Cyrille, Benboubker, Lotfi, Decaux, Olivier, Escoffre-Barbe, Martine, Michallet, Mauricette, Caillot, Denis, Fermand, Jean Paul, Avet-Loiseau, Hervé, and Facon, Thierry
- Published
- 2013
- Full Text
- View/download PDF
13. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.
- Author
-
UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Roussel, Murielle, Lauwers-Cances, Valérie, Macro, Margaret, Leleu, Xavier, Royer, Bruno, Hulin, Cyrille, Karlin, Lionel, Perrot, Aurore, Touzeau, Cyrille, Chrétien, Marie-Lorraine, Rigaudeau, Sophie, Dib, Mamoun, Nicolas-Virelizier, Emmanuelle, Escoffre-Barbe, Martine, Belhadj, Karim, Mariette, Clara, Stoppa, Anne-Marie, Araujo, Carla, Doyen, Chantal, Fontan, Jean, Kolb, Brigitte, Garderet, Laurent, Brechignac, Sabine, Malfuson, Jean-Valère, Jaccard, Arnaud, Lenain, Pascal, Borel, Cécile, Hebraud, Benjamin, Benbrahim, Omar, Dorvaux, Véronique, Manier, Salomon, Augeul-Meunier, Karine, Vekemans, Marie-Christiane, Randriamalala, Edouard, Chaoui, Driss, Caers, Jo, Chaleteix, Carine, Benboubker, Lofti, Vincent, Laure, Glaisner, Sylvie, Zunic, Patricia, Slama, Borhane, Eveillard, Jean-Richard, Humbrecht-Kraut, Catherine, Morel, Véronique, Mineur, Philippe, Eisenmann, Jean-Claude, Demarquette, Hélène, Richez, Valentine, Vignon, Marguerite, Caillot, Denis, Facon, Thierry, Moreau, Philippe, Colin, Anne-Laurène, Olivier, Pascale, Wuilleme, Soraya, Avet-Loiseau, Hervé, Corre, Jill, Attal, Michel, UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Roussel, Murielle, Lauwers-Cances, Valérie, Macro, Margaret, Leleu, Xavier, Royer, Bruno, Hulin, Cyrille, Karlin, Lionel, Perrot, Aurore, Touzeau, Cyrille, Chrétien, Marie-Lorraine, Rigaudeau, Sophie, Dib, Mamoun, Nicolas-Virelizier, Emmanuelle, Escoffre-Barbe, Martine, Belhadj, Karim, Mariette, Clara, Stoppa, Anne-Marie, Araujo, Carla, Doyen, Chantal, Fontan, Jean, Kolb, Brigitte, Garderet, Laurent, Brechignac, Sabine, Malfuson, Jean-Valère, Jaccard, Arnaud, Lenain, Pascal, Borel, Cécile, Hebraud, Benjamin, Benbrahim, Omar, Dorvaux, Véronique, Manier, Salomon, Augeul-Meunier, Karine, Vekemans, Marie-Christiane, Randriamalala, Edouard, Chaoui, Driss, Caers, Jo, Chaleteix, Carine, Benboubker, Lofti, Vincent, Laure, Glaisner, Sylvie, Zunic, Patricia, Slama, Borhane, Eveillard, Jean-Richard, Humbrecht-Kraut, Catherine, Morel, Véronique, Mineur, Philippe, Eisenmann, Jean-Claude, Demarquette, Hélène, Richez, Valentine, Vignon, Marguerite, Caillot, Denis, Facon, Thierry, Moreau, Philippe, Colin, Anne-Laurène, Olivier, Pascale, Wuilleme, Soraya, Avet-Loiseau, Hervé, Corre, Jill, and Attal, Michel
- Abstract
High-dose melphalan (HDM) and transplantation are recommended for eligible patients with multiple myeloma. No other conditioning regimen has proven to be more effective and/or safer. We previously reported in a phase 2 study that bortezomib can safely and effectively be combined with HDM (Bor-HDM), with a 32% complete response (CR) rate after transplantation. These data supported a randomized phase 3 trial. Randomization was stratified according to risk and response to induction: 300 patients were enrolled, and 154 were allocated to the experimental arm (ie, arm A) with bortezomib (1 mg/m2 intravenously [IV]) on days -6, -3, +1, and +4 and melphalan (200 mg/m2 IV) on day -2. The control arm (ie, arm B) consisted of HDM alone (200 mg/m2 IV). There were no differences in stringent CR + CR rates at day 60 posttransplant (primary end point): 22.1% in arm A vs 20.5% in arm B (P = .844). There were also no differences in undetectable minimum residual disease rates: 41.3% vs 39.4% (P = .864). Median progression-free survival was 34.0 months for arm A vs 29.6 months for arm B (adjusted HR, 0.82; 95% CI, 0.61-1.13; P = .244). The estimated 3-year overall survival was 89.5% in both arms (hazard ratio, 1.28; 95% CI, 0.62-2.64; P = .374). Sixty-nine serious adverse events occurred in 18.7% of Bor-HDM-treated patients (vs 13.1% in HDM-treated patients). The proportion of grade 3/4 AEs was similar within the 2 groups (72.0% vs 73.1%), mainly (as expected) blood and gastrointestinal disorders; 4% of patients reported grade 3/4 or painful peripheral neuropathy in arm A (vs 1.5% in arm B). In this randomized phase 3 study, a conditioning regimen with Bor-HDM did not improve efficacy end points or outcomes compared with HDM alone. The original trial was registered at www.clinicaltrials.gov as #NCT02197221.
- Published
- 2022
14. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myélome (IFM)
- Author
-
Roussel, Murielle, Moreau, Philippe, Huynh, Anne, Mary, Jean-Yves, Danho, Clotaire, Caillot, Denis, Hulin, Cyrille, Fruchart, Christophe, Marit, Gérald, Pégourié, Brigitte, Lenain, Pascal, Araujo, Carla, Kolb, Brigitte, Randriamalala, Edouard, Royer, Bruno, Stoppa, Anne-Marie, Dib, Mammoun, Dorvaux, Véronique, Garderet, Laurent, Mathiot, Claire, Avet-Loiseau, Hervé, Harousseau, Jean-Luc, Attal, Michel, and Intergroupe Francophone du Myélome (IFM)
- Published
- 2010
- Full Text
- View/download PDF
15. Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study
- Author
-
Hulin, Cyrille, primary, Offner, Fritz, additional, Moreau, Philippe, additional, Roussel, Murielle, additional, Belhadj, Karim, additional, Benboubker, Lotfi, additional, Caillot, Denis, additional, Facon, Thierry, additional, Garderet, Laurent, additional, Kuhnowski, Frédérique, additional, Stoppa, Anne-Marie, additional, Kolb, Brigitte, additional, Tiab, Mourad, additional, Jie, Kon-Siong, additional, Westerman, Matthijs, additional, Lambert, Jérôme, additional, Pei, Lixia, additional, Vanquickelberghe, Veronique, additional, De Boer, Carla, additional, Vermeulen, Jessica, additional, Kampfenkel, Tobias, additional, Sonneveld, Pieter, additional, and Van de Donk, Niels W.C.J., additional
- Published
- 2021
- Full Text
- View/download PDF
16. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia
- Author
-
Letestu, Rémi, Dahmani, Abdelmalek, Boubaya, Marouane, Baseggio, Lucile, Campos, Lydia, Chatelain, Bernard, Debliquis, Agathe, Drénou, Bernard, Jacob, Marie-Christine, Legac, Eric, Le Garff-Tavernier, Magali, Lhoumeau, Anne-Catherine, Quiney, Claire, Robillard, Nelly, Ticchioni, Michel, Aanei, Carmen, Katsahian, Sandrine, Delepine, Roselyne, Vaudaux, Sandrine, Rouillé, Valérie, Béné, Marie-Christine, Dartigeas, Caroline, Van Den Neste, Eric, Leprêtre, Stéphane, Feugier, Pierre, Cartron, Guillaume, Leblond, Véronique, Lévy, Vincent, Cymbalista, Florence, Cailleres, Sylvie, Damaj, Gandhi, Royer, Bruno, Gardembas, Martine, Dib, Mamoun, Truchan-Graczyk, Matgorzata, Hunault, Mathilde, Foussard, Charles, Corront, Bernadette, Parry, Anne, Orsini-Piocelle, Frédérique, Trouillier, Sébastien, Slama, Bohiane, Lepeu, Gérard, Zerazhi, Hacene, Boulat, Olivier, Azzedine, Ahmed, Araujo, Carla, Banos, Anne, Bauduer, Frédéric, Dutel, Jean-Luc, Ghomari, Kamel, Deconinck, Eric, Brion, Annie, Vuillier, Jacqueline, Saad, Alain, El Yamani, Abderrazak, Rodon, Philippe, Soubeyran, Pierre, Etienne, Gabriel, Dilhuydy, Marie-Sarah, Bouabdallah, Krimo, Leguay, Thibaut, Chouffi, Bachra, Pollet, Bertrand, Maakaroun, Abdallah, Guillerm, Gaëlle, Berthou, Christian, Cheron, Nathalie, ANDRÉ, Marc, Vilque, Jean Pierre, Fruchart, Christophe, Voillat, Laurent, Pica, Gian Matteo, Corm, Sélim, Micléa, Jean-Michel, Souleau, Bertrand, Molucon-Chabrot, Cécile, De Renzis, Benoit, Tournilhac, Olivier, Bay, Jacques-Olivier, Chaleteix, Carine, Guieze, Romain, Fleury, Joel, Precupanu, Cristina, Bouledroua, Selwa, Haiat, Stéphanie, Petitdidier, Charlotte, Dupuis, Jehan, Belhadj, Karim, Casasnovas, Olivier, Bastie, Jean-Noel, Ferrant, Emmanuelle, Gholam, Dany, Molina, Lysiane, Garban, Frédéric, Tiab, Mourad, Maisonneuve, Hervé, Villemagne, Bruno, Jacomy, Dominique, Besson, Caroline, Tertian, Gérard, Laribi, Kamel, Morel, Pierre, Cazin, Bruno, Moreau, Stéphane, Reminieras, Liliane, Rapp, Marie-José, Moreau, Philippe, Sebban, Catherine, Michallet, Anne-Sophie, Salles, Gilles, Broussais, Florence, Aurran-Schleinitz, Thérèse, Coso, Diane, Abarah, Wajed, Kulekci, Claire, Dorvaux, Véronique, Carassou, Philippe, Guibaud, Isabelle, Christian, Bernard, Graux, Carlos, Rossi, Jean-François, Quittet, Philippe, Dubois, Alain, Eisenmann, Jean-Claude, Morineau, Nadine, Mahé, Béatrice, Karsenti, Jean-Michel, Jourdan, Eric, Legouffe, Eric, Alexis-Vigier, Magda, Boulet, Jean-Michel, Aoudjhane, Malek, Thiéblemont, Catherine, Andreoli, Anna Lisa, Dreyfus, François, Choquet, Sylvain, Maloum, Karim, Merle-Béral, Hélène, Vekhoff, Anne, Decaudin, Didier, Brault, Philippe, Delarue, Richard, Janvier, Maud, Soussain, Carole, Vallantin, Xavier, Sanhes, Laurence, Dreyfus, Brigitte, Tomowiak, Cécile, Benramdane, Riad, Gonzalez, Hugo, Blaise-Brenna, Anne, Kolb, Brigitte, Delmer, Alain, Dauriac, Charles, Houot, Roch, Escoffre-Barbe, Martine, Lamy, Thierry, De Guibert, Sophie, Bernard, Marc, Grosbois, Bernard, Brehar, Oana, Morice, Patrick, Guyotat, Denis, Jaubert, Jérome, Portois, Christelle, Fornecker, Luc-Matthieu, Herbrecht, Raoul, Bilger, Karin, Ame, Shanti, Ysebaert, Loic, Godmer, Pascal, Jardel, Henry, Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), CHU Saint-Etienne, CHU UCL Namur, Groupe hospitalier de la région de Mulhouse Sud-Alsace (GHRMSA), CHU Grenoble, Centre Hospitalier Régional d'Orléans (CHRO), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Nice (CHU Nice), Hopital Saint-Louis [AP-HP] (AP-HP), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université Catholique de Louvain = Catholic University of Louvain (UCL), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Université de Montpellier (UM), UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (MGD) Laboratoire de biologie clinique, UCL - (SLuc) Service d'hématologie, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)
- Subjects
0301 basic medicine ,Male ,Cancer Research ,Neoplasm, Residual ,MESH: Immunotherapy ,Chronic lymphocytic leukemia ,Gastroenterology ,MESH: Clinical Trials, Phase III as Topic ,0302 clinical medicine ,Bone Marrow ,hemic and lymphatic diseases ,Antineoplastic Combined Chemotherapy Protocols ,MESH: Leukemia, Lymphocytic, Chronic, B-Cell ,MESH: Aged ,education.field_of_study ,[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology ,Hematology ,MESH: Follow-Up Studies ,Prognosis ,3. Good health ,Fludarabine ,Survival Rate ,Leukemia ,MESH: Antineoplastic Combined Chemotherapy Protocols ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,MESH: Vidarabine ,MESH: Bone Marrow ,Female ,MESH: Rituximab ,Immunotherapy ,Rituximab ,MESH: Clinical Trials, Phase II as Topic ,Vidarabine ,medicine.drug ,medicine.medical_specialty ,Cyclophosphamide ,MESH: Survival Rate ,Population ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,MESH: Prognosis ,03 medical and health sciences ,Clinical Trials, Phase II as Topic ,Chemoimmunotherapy ,Internal medicine ,medicine ,Humans ,education ,Survival rate ,MESH: Neoplasm, Residual ,Aged ,Retrospective Studies ,MESH: Humans ,business.industry ,MESH: Cyclophosphamide ,MESH: Retrospective Studies ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,MESH: Male ,body regions ,030104 developmental biology ,Clinical Trials, Phase III as Topic ,Bone marrow ,business ,MESH: Female ,Follow-Up Studies - Abstract
International audience; Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2010FMP) enabled investigation of the prognostic value of high-sensitivity (0.7 × 10-5) MRD assessment using flow cytometry, in blood (N = 401) and bone marrow (N = 339), after fludarabine, cyclophosphamide, and rituximab (FCR)-based chemoimmunotherapy in a homogeneous population with long follow-up (median 49.5 months). Addition of low-level positive MRD
- Published
- 2020
17. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial
- Author
-
Facon, Thierry, Mary, Jean Yves, Hulin, Cyrille, Benboubker, Lotfi, Attal, Michel, Pegourie, Brigitte, Renaud, Marc, Harousseau, Jean Luc, Guillerm, Gaëlle, Chaleteix, Carine, Dib, Mamoun, Voillat, Laurent, Maisonneuve, Hervé, Troncy, Jacques, Dorvaux, Véronique, Monconduit, Mathieu, Martin, Claude, Casassus, Philippe, Jaubert, Jérôme, Jardel, Henry, Doyen, Chantal, Kolb, Brigitte, Anglaret, Bruno, Grosbois, Bernard, Yakoub-Agha, Ibrahim, Mathiot, Claire, and Avet-Loiseau, Hervé
- Published
- 2007
- Full Text
- View/download PDF
18. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
- Author
-
Attal, Michel, primary, Richardson, Paul G, additional, Rajkumar, S Vincent, additional, San-Miguel, Jesus, additional, Beksac, Meral, additional, Spicka, Ivan, additional, Leleu, Xavier, additional, Schjesvold, Fredrik, additional, Moreau, Philippe, additional, Dimopoulos, Meletios A, additional, Huang, Jeffrey Shang-Yi, additional, Minarik, Jiri, additional, Cavo, Michele, additional, Prince, H Miles, additional, Macé, Sandrine, additional, Corzo, Kathryn P, additional, Campana, Frank, additional, Le-Guennec, Solenn, additional, Dubin, Franck, additional, Anderson, Kenneth C, additional, Attal, Michel, additional, Richardson, Paul G., additional, Rajkumar, Vincent, additional, Dimopoulos, Meletios A., additional, Prince, H. Miles, additional, Corzo, Kathryn P., additional, Anderson, Kenneth C., additional, Harrison, Simon, additional, Janowski, Wojt, additional, Kerridge, Ian, additional, Spencer, Andrew, additional, Delforge, Michel, additional, Fostier, Karel, additional, Vlummens, Philip, additional, Wu, Ka Lung, additional, Leblanc, Richard, additional, Pavic, Michel, additional, Sebag, Michael, additional, Hajek, Roman, additional, Maisnar, Vladimir, additional, Pour, Ludek, additional, Gregersen, Henrik, additional, Benbouker, Lotfi, additional, Caillot, Denis, additional, Escoffre-Barbe, Martine, additional, Facon, Thierry, additional, Frenzel, Laurent, additional, Hulin, Cyrille, additional, Karlin, Lionel, additional, Kolb, Brigitte, additional, Pegourie, Brigitte, additional, Perrot, Aurore, additional, Tiab, Mourad, additional, Vincent, Laure, additional, Niederwieser, Dietger, additional, Anagnostopoulos, Achilles, additional, Delimpasi, Sosana, additional, Kyrtsonis, Marie-Christine, additional, Symeonidis, Anargyros, additional, Illes, Arpad, additional, Mikala, Gabor, additional, Nagy, Zsolt, additional, Bringen, Sara, additional, Corradini, Paolo, additional, Fabio, Ciceri, additional, Lemoli, Roberto, additional, Liberati, Anna, additional, Nozzoli, Chiara, additional, Zambello, Renato, additional, Iida, Shinsuke, additional, Ikeda, Takashi, additional, Iyama, Satoshi, additional, Matsumoto, Morio, additional, Shimazaki, Chihiro, additional, Sunami, Kazutaka, additional, Suzuki, Kenshi, additional, Uchiyama, Michihiro, additional, Koh, Youngil, additional, Kim, Kihyun, additional, Lee, Jae Hoon, additional, Min, Chang-Ki, additional, Blacklock, Hillary, additional, Goodman, Hugh, additional, Neylon, Annette, additional, Simpson, David, additional, Grosicki, Sebastian, additional, Jurczyszyn, Artur, additional, Walter-Croneck, Adam, additional, Warzocha, Krzysztof, additional, Araujo, Luis, additional, Moreira, Claudia, additional, Doronin, Vadim, additional, Mendeleeva, Larisa, additional, Vorobyev, Vladimir, additional, Vranovsky, Andrej, additional, Alegre, Adrian, additional, Gironella, Mercedes, additional, Gonzalez Perez, Marta Sonia, additional, Montes, Carmen, additional, Ocio, Enrique, additional, Rodriguez, Paula, additional, Hardling, Mats, additional, Lauri, Birgitta, additional, Wang, Ming-Chung, additional, Yeh, Su-Peng, additional, Arat, Mutlu, additional, Demirkan, Fatih, additional, Gulbas, Zafer, additional, Besisik, Sevgi Kalayoglu, additional, Karadogan, Ihsan, additional, Tuglular, Tulin, additional, Unal, Ali, additional, Vural, Filiz, additional, Sive, Jonathan, additional, Streetly, Matthew, additional, Yong, Kwee, additional, and Tache, Jason, additional
- Published
- 2019
- Full Text
- View/download PDF
19. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
- Author
-
UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (MGD) Service d'hématologie, UCL - (SLuc) Service d'hématologie, Moreau, Philippe, Attal, Michel, Hulin, Cyrille, Arnulf, Bertrand, Belhadj, Karim, Benboubker, Lotfi, Béné, Marie C, Broijl, Annemiek, Caillon, Hélène, Caillot, Denis, Corre, Jill, Delforge, Michel, Dejoie, Thomas, Doyen, Chantal, Facon, Thierry, Sonntag, Cécile, Fontan, Jean, Garderet, Laurent, Jie, Kon-Siong, Karlin, Lionel, Kuhnowski, Frédérique, Lambert, Jérôme, Leleu, Xavier, Lenain, Pascal, Macro, Margaret, Mathiot, Claire, Orsini-Piocelle, Frédérique, Perrot, Aurore, Stoppa, Anne-Marie, van de Donk, Niels Wcj, Wuilleme, Soraya, Zweegman, Sonja, Kolb, Brigitte, Touzeau, Cyrille, Roussel, Murielle, Tiab, Mourad, Marolleau, Jean-Pierre, Meuleman, Nathalie, Vekemans, Marie-Christiane, Westerman, Matthijs, Klein, Saskia K, Levin, Mark-David, Fermand, Jean Paul, Escoffre-Barbe, Martine, Eveillard, Jean-Richard, Garidi, Reda, Ahmadi, Tahamtan, Zhuang, Sen, Chiu, Christopher, Pei, Lixia, de Boer, Carla, Smith, Elena, Deraedt, William, Kampfenkel, Tobias, Schecter, Jordan, Vermeulen, Jessica, Avet-Loiseau, Hervé, Sonneveld, Pieter, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (MGD) Service d'hématologie, UCL - (SLuc) Service d'hématologie, Moreau, Philippe, Attal, Michel, Hulin, Cyrille, Arnulf, Bertrand, Belhadj, Karim, Benboubker, Lotfi, Béné, Marie C, Broijl, Annemiek, Caillon, Hélène, Caillot, Denis, Corre, Jill, Delforge, Michel, Dejoie, Thomas, Doyen, Chantal, Facon, Thierry, Sonntag, Cécile, Fontan, Jean, Garderet, Laurent, Jie, Kon-Siong, Karlin, Lionel, Kuhnowski, Frédérique, Lambert, Jérôme, Leleu, Xavier, Lenain, Pascal, Macro, Margaret, Mathiot, Claire, Orsini-Piocelle, Frédérique, Perrot, Aurore, Stoppa, Anne-Marie, van de Donk, Niels Wcj, Wuilleme, Soraya, Zweegman, Sonja, Kolb, Brigitte, Touzeau, Cyrille, Roussel, Murielle, Tiab, Mourad, Marolleau, Jean-Pierre, Meuleman, Nathalie, Vekemans, Marie-Christiane, Westerman, Matthijs, Klein, Saskia K, Levin, Mark-David, Fermand, Jean Paul, Escoffre-Barbe, Martine, Eveillard, Jean-Richard, Garidi, Reda, Ahmadi, Tahamtan, Zhuang, Sen, Chiu, Christopher, Pei, Lixia, de Boer, Carla, Smith, Elena, Deraedt, William, Kampfenkel, Tobias, Schecter, Jordan, Vermeulen, Jessica, Avet-Loiseau, Hervé, and Sonneveld, Pieter
- Abstract
BACKGROUND: Bortezomib, thalidomide, and dexamethasone (VTd) plus autologous stem-cell transplantation is standard treatment in Europe for transplant-eligible patients with newly diagnosed multiple myeloma. We evaluated whether the addition of daratumumab to VTd before and after autologous stem-cell transplantation would improve stringent complete response rate in patients with newly diagnosed multiple myeloma. METHODS: In this two-part, randomised, open-label, phase 3 CASSIOPEIA trial, we recruited transplant-eligible patients with newly diagnosed multiple myeloma at 111 European sites. Patients were randomly assigned (1:1) to receive four pre-transplant induction and two post-transplant consolidation cycles of VTd alone (VTd group) or in combination with daratumumab (D-VTd group). The primary endpoint of part 1 was stringent complete response assessed 100 days after transplantation. Part 2 (maintenance) is ongoing. The trial is registered with ClinicalTrials.gov, number NCT02541383. FINDINGS: Between Sept 22, 2015, and Aug 1, 2017, 1085 patients were enrolled at 111 European sites and were randomly assigned to the D-VTd group (n=543) or the VTd group (n=542). At day 100 after transplantation, 157 (29%) of 543 patients in the D-VTd group and 110 (20%) of 542 patients in the VTd group in the intention-to-treat population had achieved a stringent complete response (odds ratio 1·60, 95% CI 1·21-2·12, p=0·0010). 211 (39%) patients in the D-VTd group versus 141 (26%) in the VTd group achieved a complete response or better, and 346 (64%) of 543 versus 236 (44%) of 542 achieved minimal residual disease-negativity (10-5 sensitivity threshold, assessed by multiparametric flow cytometry; both p<0·0001). Median progression-free survival from first randomisation was not reached in either group (hazard ratio 0·47, 95% CI 0·33-0·67, p<0·0001). 46 deaths on study were observed (14 vs 32, 0·43, 95% CI 0·23-0·80). The most common grade 3 or 4 adverse events were neutropenia (28% vs
- Published
- 2019
20. Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.
- Author
-
UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Pertesi, Maroulio, Vallée, Maxime, Wei, Xiaomu, Revuelta, Maria V, Galia, Perrine, Demangel, Delphine, Oliver, Javier, Foll, Matthieu, Chen, Siwei, Perrial, Emeline, Garderet, Laurent, Corre, Jill, Leleu, Xavier, Boyle, Eileen M, Decaux, Olivier, Rodon, Philippe, Kolb, Brigitte, Slama, Borhane, Mineur, Philippe, Voog, Eric, Le Bris, Catherine, Fontan, Jean, Maigre, Michel, Beaumont, Marie, Azais, Isabelle, Sobol, Hagay, Vignon, Marguerite, Royer, Bruno, Perrot, Aurore, Fuzibet, Jean-Gabriel, Dorvaux, Véronique, Anglaret, Bruno, Cony-Makhoul, Pascale, Berthou, Christian, Desquesnes, Florence, Pegourie, Brigitte, Leyvraz, Serge, Mosser, Laurent, Frenkiel, Nicole, Augeul-Meunier, Karine, Leduc, Isabelle, Leyronnas, Cécile, Voillat, Laurent, Casassus, Philippe, Mathiot, Claire, Cheron, Nathalie, Paubelle, Etienne, Moreau, Philippe, Bignon, Yves-Jean, Joly, Bertrand, Bourquard, Pascal, Caillot, Denis, Naman, Hervé, Rigaudeau, Sophie, Marit, Gérald, Macro, Margaret, Lambrecht, Isabelle, Cliquennois, Manuel, Vincent, Laure, Helias, Philippe, Avet-Loiseau, Hervé, Moreno, Victor, Reis, Rui Manuel, Varkonyi, Judit, Kruszewski, Marcin, Vangsted, Annette Juul, Jurczyszyn, Artur, Zaucha, Jan Maciej, Sainz, Juan, Krawczyk-Kulis, Malgorzata, Wątek, Marzena, Pelosini, Matteo, Iskierka-Jażdżewska, Elzbieta, Grząśko, Norbert, Martinez-Lopez, Joaquin, Jerez, Andrés, Campa, Daniele, Buda, Gabriele, Lesueur, Fabienne, Dudziński, Marek, García-Sanz, Ramón, Nagler, Arnon, Rymko, Marcin, Jamroziak, Krzysztof, Butrym, Aleksandra, Canzian, Federico, Obazee, Ofure, Nilsson, Björn, Klein, Robert J, Lipkin, Steven M, McKay, James D, Dumontet, Charles, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Pertesi, Maroulio, Vallée, Maxime, Wei, Xiaomu, Revuelta, Maria V, Galia, Perrine, Demangel, Delphine, Oliver, Javier, Foll, Matthieu, Chen, Siwei, Perrial, Emeline, Garderet, Laurent, Corre, Jill, Leleu, Xavier, Boyle, Eileen M, Decaux, Olivier, Rodon, Philippe, Kolb, Brigitte, Slama, Borhane, Mineur, Philippe, Voog, Eric, Le Bris, Catherine, Fontan, Jean, Maigre, Michel, Beaumont, Marie, Azais, Isabelle, Sobol, Hagay, Vignon, Marguerite, Royer, Bruno, Perrot, Aurore, Fuzibet, Jean-Gabriel, Dorvaux, Véronique, Anglaret, Bruno, Cony-Makhoul, Pascale, Berthou, Christian, Desquesnes, Florence, Pegourie, Brigitte, Leyvraz, Serge, Mosser, Laurent, Frenkiel, Nicole, Augeul-Meunier, Karine, Leduc, Isabelle, Leyronnas, Cécile, Voillat, Laurent, Casassus, Philippe, Mathiot, Claire, Cheron, Nathalie, Paubelle, Etienne, Moreau, Philippe, Bignon, Yves-Jean, Joly, Bertrand, Bourquard, Pascal, Caillot, Denis, Naman, Hervé, Rigaudeau, Sophie, Marit, Gérald, Macro, Margaret, Lambrecht, Isabelle, Cliquennois, Manuel, Vincent, Laure, Helias, Philippe, Avet-Loiseau, Hervé, Moreno, Victor, Reis, Rui Manuel, Varkonyi, Judit, Kruszewski, Marcin, Vangsted, Annette Juul, Jurczyszyn, Artur, Zaucha, Jan Maciej, Sainz, Juan, Krawczyk-Kulis, Malgorzata, Wątek, Marzena, Pelosini, Matteo, Iskierka-Jażdżewska, Elzbieta, Grząśko, Norbert, Martinez-Lopez, Joaquin, Jerez, Andrés, Campa, Daniele, Buda, Gabriele, Lesueur, Fabienne, Dudziński, Marek, García-Sanz, Ramón, Nagler, Arnon, Rymko, Marcin, Jamroziak, Krzysztof, Butrym, Aleksandra, Canzian, Federico, Obazee, Ofure, Nilsson, Björn, Klein, Robert J, Lipkin, Steven M, McKay, James D, and Dumontet, Charles
- Abstract
To the Editor, Multiple myeloma (MM) is the third most common hematological malignancy, after Non-Hodgkin Lymphoma and Leukemia. MM is generally preceded by Monoclonal Gammopathy of Undetermined Significance (MGUS) [1], and epidemiological studies have identified older age, male gender, family history, and MGUS as risk factors for developing MM [...]
- Published
- 2019
21. Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.
- Author
-
Leleu, Xavier, Fouquet, Guillemette, Richez, Valentine, Guidez, Stéphanie, Duhamel, Alain, Machuron, François, Karlin, Lionel, Kolb, Brigitte, Tiab, Mourad, Araujo, Carla, Meuleman, Nathalie, Malfuson, Jean Valère, Bourquard, Pascal, Lenain, Pascal, Roussel, Murielle, Jaccard, Arnaud, Pétillon, Marie-Odile, Belhadj-Merzoug, Karim, Lepeu, Gérard, Chrétien, Marie-Lorraine, Fontan, Jean, Rodon, Philippe, Schmitt, Anna, Offner, Fritz, Voillat, Laurent, Cereja, Sophie, Kuhnowski, Frédérique, Rigaudeau, Sophie, Decaux, Olivier, Humbrecht-Kraut, Catherine, Frayfer, Jamile, Fitoussi, Olivier, Roos-Weil, Damien, Eisenmann, Jean Claude, Dorvaux, Véronique, Voog, Eric G, Attal, Michel, Moreau, Philippe, Avet-Loiseau, Herve, Hulin, Cyrille, Facon, Thierry, Leleu, Xavier, Fouquet, Guillemette, Richez, Valentine, Guidez, Stéphanie, Duhamel, Alain, Machuron, François, Karlin, Lionel, Kolb, Brigitte, Tiab, Mourad, Araujo, Carla, Meuleman, Nathalie, Malfuson, Jean Valère, Bourquard, Pascal, Lenain, Pascal, Roussel, Murielle, Jaccard, Arnaud, Pétillon, Marie-Odile, Belhadj-Merzoug, Karim, Lepeu, Gérard, Chrétien, Marie-Lorraine, Fontan, Jean, Rodon, Philippe, Schmitt, Anna, Offner, Fritz, Voillat, Laurent, Cereja, Sophie, Kuhnowski, Frédérique, Rigaudeau, Sophie, Decaux, Olivier, Humbrecht-Kraut, Catherine, Frayfer, Jamile, Fitoussi, Olivier, Roos-Weil, Damien, Eisenmann, Jean Claude, Dorvaux, Véronique, Voog, Eric G, Attal, Michel, Moreau, Philippe, Avet-Loiseau, Herve, Hulin, Cyrille, and Facon, Thierry
- Abstract
Carfilzomib is a novel generation proteasome inhibitor. The Carmysap trial demonstrated that twice-weekly KMP (carfilzomib, melphalan, prednisone) might challenge the MPV (melphalan, prednisone, bortezomib) standard. We sought to study KMP weekly, allowing to increase carfilzomib's dose with maintained efficacy and improved safety profile., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2019
22. Maintenance with Weekly Carfilzomib in Elderly Newly Diagnosed Multiple Myeloma (IFM 2012-03)
- Author
-
Bobin, Arthur, primary, Fouquet, Guillemette, additional, Duhamel, Alain, additional, Manier, Salomon, additional, Karlin, Lionel, additional, Kolb, Brigitte, additional, Tiab, Mourad, additional, Araujo, Carla, additional, Meuleman, Nathalie, additional, Malfuson, Jean Valère, additional, Bourquard, Pascal, additional, Lenain, Pascal, additional, Jaccard, Arnaud, additional, Belhadj, Karim, additional, Attal, Michel, additional, Moreau, Philippe, additional, Hulin, Cyrille, additional, and Leleu, Xavier, additional
- Published
- 2019
- Full Text
- View/download PDF
23. Evolving Treatment Trends in Relapsed/Refractory Multiple Myeloma (RRMM) in Europe from 2016 to 2018: Analysis of a Multi-National Survey
- Author
-
Merz, Maximilian, primary, Vande Broek, Isabelle, additional, Pérez, Manuel, additional, Kolb, Brigitte, additional, Symeonidis, Argiris, additional, Nikolousis, Emmanouil, additional, Zomas, Athanasios, additional, Gonzalez, Francisco, additional, Kellermann, Lenka, additional, and Goldschmidt, Hartmut, additional
- Published
- 2019
- Full Text
- View/download PDF
24. Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
- Author
-
Leleu, Xavier, primary, Fouquet, Guillemette, additional, Richez, Valentine, additional, Guidez, Stéphanie, additional, Duhamel, Alain, additional, Machuron, François, additional, Karlin, Lionel, additional, Kolb, Brigitte, additional, Tiab, Mourad, additional, Araujo, Carla, additional, Meuleman, Nathalie, additional, Malfuson, Jean-Valère, additional, Bourquard, Pascal, additional, Lenain, Pascal, additional, Roussel, Murielle, additional, Jaccard, Arnaud, additional, Pétillon, Marie-Odile, additional, Belhadj-Merzoug, Karim, additional, Lepeu, Gérard, additional, Chrétien, Marie-Lorraine, additional, Fontan, Jean, additional, Rodon, Philippe, additional, Schmitt, Anna, additional, Offner, Fritz, additional, Voillat, Laurent, additional, Cereja, Sophie, additional, Kuhnowski, Frédérique, additional, Rigaudeau, Sophie, additional, Decaux, Olivier, additional, Humbrecht-Kraut, Catherine, additional, Frayfer, Jamile, additional, Fitoussi, Olivier, additional, Roos-Weil, Damien, additional, Eisenmann, Jean-Claude, additional, Dorvaux, Véronique, additional, Voog, Eric G., additional, Attal, Michel, additional, Moreau, Philippe, additional, Avet-Loiseau, Hervé, additional, Hulin, Cyrille, additional, and Facon, Thierry, additional
- Published
- 2019
- Full Text
- View/download PDF
25. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
- Author
-
Moreau, Philippe, primary, Attal, Michel, additional, Hulin, Cyrille, additional, Arnulf, Bertrand, additional, Belhadj, Karim, additional, Benboubker, Lotfi, additional, Béné, Marie C, additional, Broijl, Annemiek, additional, Caillon, Hélène, additional, Caillot, Denis, additional, Corre, Jill, additional, Delforge, Michel, additional, Dejoie, Thomas, additional, Doyen, Chantal, additional, Facon, Thierry, additional, Sonntag, Cécile, additional, Fontan, Jean, additional, Garderet, Laurent, additional, Jie, Kon-Siong, additional, Karlin, Lionel, additional, Kuhnowski, Frédérique, additional, Lambert, Jérôme, additional, Leleu, Xavier, additional, Lenain, Pascal, additional, Macro, Margaret, additional, Mathiot, Claire, additional, Orsini-Piocelle, Frédérique, additional, Perrot, Aurore, additional, Stoppa, Anne-Marie, additional, van de Donk, Niels WCJ, additional, Wuilleme, Soraya, additional, Zweegman, Sonja, additional, Kolb, Brigitte, additional, Touzeau, Cyrille, additional, Roussel, Murielle, additional, Tiab, Mourad, additional, Marolleau, Jean-Pierre, additional, Meuleman, Nathalie, additional, Vekemans, Marie-Christiane, additional, Westerman, Matthijs, additional, Klein, Saskia K, additional, Levin, Mark-David, additional, Fermand, Jean Paul, additional, Escoffre-Barbe, Martine, additional, Eveillard, Jean-Richard, additional, Garidi, Reda, additional, Ahmadi, Tahamtan, additional, Zhuang, Sen, additional, Chiu, Christopher, additional, Pei, Lixia, additional, de Boer, Carla, additional, Smith, Elena, additional, Deraedt, William, additional, Kampfenkel, Tobias, additional, Schecter, Jordan, additional, Vermeulen, Jessica, additional, Avet-Loiseau, Hervé, additional, and Sonneveld, Pieter, additional
- Published
- 2019
- Full Text
- View/download PDF
26. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.
- Author
-
UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Perrot, Aurore, Lauwers-Cances, Valerie, Corre, Jill, Robillard, Nelly, Hulin, Cyrille, Chretien, Marie-Lorraine, Dejoie, Thomas, Maheo, Sabrina, Stoppa, Anne-Marie, Pegourie, Brigitte, Karlin, Lionel, Garderet, Laurent, Arnulf, Bertrand, Doyen, Chantal, Meuleman, Nathalie, Royer, Bruno, Eveillard, Jean-Richard, Benboubker, Lotfi, Dib, Mamoun, Decaux, Olivier, Jaccard, Arnaud, Belhadj, Karim, Brechignac, Sabine, Kolb, Brigitte, Fohrer, Cecile, Mohty, Mohamad, Macro, Margaret, Richardson, Paul G, Carlton, Victoria, Moorhead, Martin, Willis, Tom, Faham, Malek, Anderson, Kenneth C, Harousseau, Jean-Luc, Leleu, Xavier, Facon, Thierry, Moreau, Philippe, Attal, Michel, Avet-Loiseau, Hervé, Munshi, Nikhil, UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Perrot, Aurore, Lauwers-Cances, Valerie, Corre, Jill, Robillard, Nelly, Hulin, Cyrille, Chretien, Marie-Lorraine, Dejoie, Thomas, Maheo, Sabrina, Stoppa, Anne-Marie, Pegourie, Brigitte, Karlin, Lionel, Garderet, Laurent, Arnulf, Bertrand, Doyen, Chantal, Meuleman, Nathalie, Royer, Bruno, Eveillard, Jean-Richard, Benboubker, Lotfi, Dib, Mamoun, Decaux, Olivier, Jaccard, Arnaud, Belhadj, Karim, Brechignac, Sabine, Kolb, Brigitte, Fohrer, Cecile, Mohty, Mohamad, Macro, Margaret, Richardson, Paul G, Carlton, Victoria, Moorhead, Martin, Willis, Tom, Faham, Malek, Anderson, Kenneth C, Harousseau, Jean-Luc, Leleu, Xavier, Facon, Thierry, Moreau, Philippe, Attal, Michel, Avet-Loiseau, Hervé, and Munshi, Nikhil
- Abstract
The introduction of novel agents has led to major improvements in clinical outcomes for patients with multiple myeloma. To shorten evaluation times for new treatments, health agencies are currently examining minimal residual disease (MRD) as a surrogate end point in clinical trials. We assessed the prognostic value of MRD, measured during maintenance therapy by next-generation sequencing (NGS). MRD negativity was defined as the absence of tumor plasma cell within 1 000 000 bone marrow cells (<10). Data were analyzed from a recent clinical trial that evaluated the role of transplantation in newly diagnosed myeloma patients treated with lenalidomide, bortezomib, and dexamethasone (RVD). MRD negativity was achieved at least once during maintenance in 127 patients (25%). At the start of maintenance therapy, MRD was a strong prognostic factor for both progression-free survival (adjusted hazard ratio, 0.22; 95% confidence interval, 0.15-0.34; < .001) and overall survival (adjusted hazard ratio, 0.24; 95% confidence interval, 0.11-0.54; = .001). Patients who were MRD negative had a higher probability of prolonged progression-free survival than patients with detectable residual disease, regardless of treatment group (RVD vs transplant), cytogenetic risk profile, or International Staging System disease stage at diagnosis. These results were similar after completion of maintenance therapy. Our findings confirm the value of MRD status, as determined by NGS, as a prognostic biomarker in multiple myeloma, and suggest that this approach could be used to adapt treatment strategies in future clinical trials.
- Published
- 2018
27. Light Chain Escape in Multiple Myeloma
- Author
-
Dejoie, Thomas, primary, Fouquet, Guillemette, additional, Hulin, Cyrille, additional, Roussel, Murielle, additional, Hebraud, Benjamin, additional, Karlin, Lionel, additional, Kolb, Brigitte, additional, Araujo, Carla, additional, Meuleman, Nathalie, additional, Tiab, Mourad, additional, Malfuson, Jean Valère, additional, Bourquard, Pascal, additional, Lenain, Pascal, additional, Jaccard, Arnaud, additional, Belhadj, Karim, additional, Lepeu, Gérard, additional, Chretien, Marie Lorraine, additional, Caillot, Denis, additional, Fontan, Jean, additional, Rodon, Philippe, additional, Schmitt, Anna, additional, Voillat, Laurent, additional, Cereja, Sophie, additional, Pegourie, Brigitte, additional, Kuhnowski, Frederique, additional, Rigaudeau, Sophie, additional, Decaux, Olivier, additional, Humbrecht-Kraut, Catherine, additional, Frayfer, Jamilé, additional, Garderet, Laurent, additional, Roos-Weil, Damien, additional, Eisenmann, Jean Claude, additional, Dorvaux, Veronique, additional, Voog, Eric G., additional, Mathiot, Claire, additional, Fermand, Jean-Paul, additional, Facon, Thierry, additional, Avet-Loiseau, Hervé, additional, Harousseau, Jean Luc, additional, Moreau, Philippe, additional, Attal, Michel, additional, and Leleu, Xavier, additional
- Published
- 2018
- Full Text
- View/download PDF
28. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma
- Author
-
Dimopoulos, Meletios A Cheung, Matthew C Roussel, Murielle Liu, Ting Gamberi, Barbara Kolb, Brigitte Derigs, H Guenter Eom, HyeonSeok Belhadj, Karim Lenain, Pascal others
- Subjects
Health Sciences ,Επιστήμες Υγείας - Published
- 2016
29. Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03) / 57th Annual Meeting of the American-Society-of-Hematology - Orlando, FL
- Author
-
Leleu, Xavier, Karlin, Lionel, Kolb, Brigitte, Tiab, Mourad, Araujo, Carla, Meuleman, Nathalie, De Revel, Thierry, Bourquard, Pascal, Lenain, Pascal, Roussel, Murielle, Jaccard, Arnaud, Petillon, Marie-Odile, Belhadj-Merzoug, Karim, Lepeu, Gerard, Chretien, Marie-Lorraine, Fontan, Jean, Rodon, Philippe, Schmitt, Anna, Offner, Fritz, Voillat, Laurent, Cereja, Sophie, Kuhnowski, Frederique, Rigaudeau, Sophie, Decaux, Olivier, Humbrecht-Kraut, Catherine, Frayfer, Jamile, Fitoussi, Olivier, Weil, Damien Roos, Eisenmann, Jean Claude, Dorvaux, Véronique, Voog, Eric G., Hulin, Cyrille, Attal, Michel, Moreau, Philippe, Facon, Thierry, Service d'Hématologie, Centre Hospitalier Universitaire de Reims (CHU Reims), Hôpital Général de La Roche sur Yon, Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), CHU Pontchaillou [Rennes], Service d'Hématologie clinique et thérapie cellulaire [CHU Limoges], CHU Limoges, Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Henri Duffaut (Avignon), Lipides - Nutrition - Cancer (U866) (LNC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bourgogne (UB)-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Service d'hématologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Chalon-sur-Saône William Morey, Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier de Meaux, Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Laboratoire d'Hématologie [Rangueil], Hôpital de Rangueil, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Service d'Hématologie Clinique, Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital Claude Huriez [Lille], CHU Lille, Jonchère, Laurent, Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service Hématologie - IUCT-Oncopole [CHU Toulouse], Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle IUCT [CHU Toulouse], and Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)
- Subjects
[SDV] Life Sciences [q-bio] ,[SDV]Life Sciences [q-bio] - Abstract
WOS:000368020103223; International audience; Conference: 57th Annual Meeting of the American-Society-of-Hematology - Orlando, FL - DEC 05-08, 2015
- Published
- 2015
30. Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria
- Author
-
Fouquet, Guillemette, primary, Snell, Kym IE, additional, Guidez, Stéphanie, additional, Schraen, Susanna, additional, Boyle, Eileen, additional, Renaud, Loïc, additional, Desmier, Déborah, additional, Machet, Antoine, additional, Moya, Niels, additional, Systchenko, Thomas, additional, Gruchet, Cécile, additional, Decaux, Olivier, additional, Arnulf, Bertrand, additional, Fohrer, Cécile, additional, Richez, Valentine, additional, Kolb, Brigitte, additional, Macro, Margaret, additional, Karlin, Lionel, additional, Royer, Bruno, additional, Pegourie, Brigitte, additional, Hebraud, Benjamin, additional, Caillot, Denis, additional, Perrot, Aurore, additional, Moreau, Philippe, additional, Facon, Thierry, additional, Avet-Loiseau, Hervé, additional, Dejoie, Thomas, additional, Hulin, Cyrille, additional, Harding, Stephen, additional, and Leleu, Xavier, additional
- Published
- 2017
- Full Text
- View/download PDF
31. Carfilzomib weekly-melphalan-prednisone in untreated elderly multiple myeloma: IFM2012-03.
- Author
-
Leleu, Xavier, primary, Fouquet, Guillemette, additional, Karlin, Lionel, additional, Kolb, Brigitte, additional, Tiab, Mourad, additional, Araujo, Carla, additional, Roussel, Murielle, additional, Bourquard, Pascal, additional, Lenain, Pascal, additional, Humbrecht-Kraut, Catherine, additional, Belhadj, Karim, additional, Petillon, Marie-Odile, additional, Chretien, Marie-Lorraine, additional, Rodon, Philippe, additional, Decaux, Olivier, additional, Jaccard, Arnaud, additional, Hulin, Cyrille, additional, Attal, Michel, additional, Moreau, Philippe, additional, and Facon, Thierry, additional
- Published
- 2017
- Full Text
- View/download PDF
32. Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03)
- Author
-
Leleu, Xavier, primary, Fouquet, Guillemette, additional, Karlin, Lionel, additional, Kolb, Brigitte, additional, Tiab, Mourad, additional, Araujo, Carla, additional, Bourquard, Pascal, additional, Lenain, Pascal, additional, Roussel, Muriel, additional, Jaccard, Arnaud, additional, Petillon, Marie-Odile, additional, Belhadj-Merzoug, Karim, additional, Lepeu, Gérard, additional, Chretien, Marie-Lorraine, additional, Fontan, Jean, additional, Rodon, Philippe, additional, Schmitt, Anna, additional, Voillat, Laurent, additional, Cereja, Sophie, additional, Kuhnowski, Frédérique, additional, Rigaudeau, Sophie, additional, Decaux, Olivier, additional, Frayfer, Jamile, additional, Fitoussi, Olivier, additional, Roos Weil, Damien, additional, Eisenmann, Jean-Claude, additional, Dorvaux, Véronique, additional, Voog, Eric, additional, Hulin, Cyrille, additional, and Attal, Michel, additional
- Published
- 2017
- Full Text
- View/download PDF
33. Treatment of Myeloma Cast Nephropathy (MCN): A Randomized Trial Comparing Intensive Haemodialysis (HD) with High Cut-Off (HCO) or Standard High-Flux Dialyzer in Patients Receiving a Bortezomib-Based Regimen (the MYRE Study, by the Intergroupe Francophone du Myélome (IFM) and the French Society of Nephrology (SFNDT))
- Author
-
Bridoux, Frank, primary, Pegourie, Brigitte, additional, Augeul-Meunier, Karine, additional, Royer, Bruno, additional, Joly, Bertrand, additional, Lamy, Thierry, additional, Kolb, Brigitte, additional, Benboubker, Lofti, additional, Arnulf, Bertrand, additional, Jaccard, Arnaud, additional, Chevret, Sylvie, additional, and Fermand, Jean-Paul, additional
- Published
- 2016
- Full Text
- View/download PDF
34. Daratumumab in Combination with Dexamethasone in Resistant or Refractory Multiple Myeloma: Primary Results of the IFM2014-04 Trial
- Author
-
Boyle, Eileen Mary, primary, Petillon, Marie-Odile, additional, Herbaux, Charles, additional, Mimouni, Johanna, additional, Leleu, Xavier, additional, Karlin, Lionel, additional, Doyen, Chantal, additional, Wetterwald, Marc, additional, Roussel, Muriel, additional, Hulin, Cyrille, additional, Royer, Bruno, additional, Macro, Margaret, additional, Moreau, Philippe, additional, Fostier, Karel, additional, Dib, Mamoun, additional, Brechignac, Sabine, additional, Bureau, Caroline, additional, Marit, Gerald, additional, Tempescul, Adrian, additional, Chretien, Marie Lorraine, additional, Zarnitsky, Charles, additional, Fohrer, Cecile, additional, Perrot, Aurore, additional, Benboubker, Lotfi, additional, Voillat, Laurent, additional, Malfuson, Jean Valere, additional, Mariette, Clara, additional, Tiab, Mourad, additional, Rigaudeau, Sophie, additional, Jaccard, Arnaud, additional, Stoppa, Anne-Marie, additional, Vincent, Laure, additional, Eisenmann, Jean Claude, additional, Frenzel, Laurent, additional, Arnulf, Bertrand, additional, Mohty, Mohamad, additional, Rodon, Philippe, additional, Kolb, Brigitte, additional, Decaux, Olivier, additional, Godmer, Pascal, additional, Beauvais, David, additional, Carpentier, Benjamin, additional, Bonnet, Sarah, additional, Longval, Thomas, additional, Dewevre, Mathieu, additional, Avet-Loiseau, Herve, additional, Attal, Michel, additional, Schraen, Susanna, additional, and Facon, Thierry, additional
- Published
- 2016
- Full Text
- View/download PDF
35. IFM2012-03
- Author
-
Leleu, Xavier, primary, Fouquet, Guillemette, additional, Karlin, Lionel, additional, Kolb, Brigitte, additional, Tiab, Mourad, additional, Araujo, Carla, additional, Meuleman, Nathalie, additional, Malfuson, Jv, additional, Bourquard, Pascal, additional, Lenain, Pascal, additional, Roussel, Murielle, additional, Jaccard, Arnaud, additional, Petillon, Marie-Odile, additional, Belhadj-Merzoug, Karim, additional, Lepeu, Gerard, additional, Chretien, Marie-Lorraine, additional, Fontan, Jean, additional, Rodon, Philippe, additional, Schmitt, Anna, additional, Offner, Fritz, additional, Voillat, Laurent, additional, Cereja, Sophie, additional, Kuhnowski, Frederique, additional, Rigaudeau, Sophie, additional, Decaux, Olivier, additional, Humbrecht-Kraut, Catherine, additional, Frayfer, Jamile, additional, Fitoussi, Olivier, additional, Roos Weil, Damien, additional, Eisenmann, Jean Claude, additional, Dorvaux, Veronique, additional, Voog, Eric G., additional, Hulin, Cyrille, additional, Attal, Michel, additional, Moreau, Philippe, additional, and Facon, Thierry, additional
- Published
- 2016
- Full Text
- View/download PDF
36. Maintenance with Weekly Carfilzomib in Elderly newly Diagnosed Multiple Myeloma (IFM 2012-03).
- Author
-
Bobin, Arthur, Fouquet, Guillemette, Manier, Salomon, Karlin, Lionel, Kolb, Brigitte, Tiab, Mourad, Araujo, Carla, Bourquard, Pascal, Lenain, Pascal, Jaccard, Arnaud, Belhadj-Merzoug, Karim, Attal, Michel, Hulin, Cyrille, Moreau, Philippe, Avet-Loiseau, Herve, and Leleu, Xavier
- Published
- 2019
- Full Text
- View/download PDF
37. Salvage Therapy Post Pomalidomide-Based Regimen in Relapsed/Refractory Myeloma
- Author
-
Fouquet, Guillemette, primary, Karlin, Lionel, additional, MACRO, Margaret, additional, Caillot, Denis, additional, Roussel, Murielle, additional, Arnulf, Bertrand, additional, Pégourie, Brigitte, additional, Petillon, Marie-Odile, additional, Marit, Gerald, additional, Mathiot, Claire, additional, Kolb, Brigitte, additional, Stoppa, Anne-Marie, additional, Brechignac, Sabine, additional, Rodon, Philippe, additional, Dib, Mamoun, additional, Tiab, Mourad, additional, Legros, Laurence, additional, Banos, Anne, additional, Wetterwald, Marc, additional, Garderet, Laurent, additional, Royer, Bruno, additional, Hulin, Cyrille, additional, Benboubker, Lotfi, additional, Decaux, Olivier, additional, Escoffre, Martine, additional, Fermand, Jean-Paul, additional, Moreau, Philippe, additional, Avet-Loiseau, Herve, additional, Attal, Michel, additional, Facon, Thierry, additional, and Leleu, Xavier, additional
- Published
- 2015
- Full Text
- View/download PDF
38. Bortezomib, Thalidomide and Dexamethasone (VTD) Is Superior to Bortezomib, Cyclophosphamide and Dexamethasone (VCD) Prior to Autologous Stem Cell Transplantation for Patients with De Novo Multiple Myeloma. Results of the Prospective IFM 2013-04 Trial
- Author
-
Moreau, Philippe, primary, Hulin, Cyrille, additional, MACRO, Margaret, additional, Caillot, Denis, additional, Chaleteix, Carine, additional, Roussel, Murielle, additional, Garderet, Laurent, additional, Royer, Bruno, additional, Brechignac, Sabine, additional, Tiab, Mourad, additional, Puyade, Mathieu, additional, Escoffre, Martine, additional, Stoppa, Anne-Marie, additional, Facon, Thierry, additional, Pégourie, Brigitte, additional, Chaoui, Driss, additional, Jaccard, Arnaud, additional, Slama, Borhane, additional, Marit, Gerald, additional, Laribi, Kamel, additional, Godmer, Pascal, additional, Luycx, Odile, additional, Eisenmann, Jean Claude, additional, Allangha, Olivier, additional, Glaisner, Sylvie, additional, Dib, Mamoun, additional, Araujo, Carla, additional, Fontan, Jean, additional, Belhadj, Karim, additional, Wetterwald, Marc, additional, Dorvaux, Veronique, additional, Fermand, Jean-Paul, additional, Rodon, Philippe, additional, Kolb, Brigitte, additional, Lenain, Pascal, additional, Planche, Lucie, additional, Biron, Laetitia, additional, Caillon, Helene, additional, Avet-Loiseau, Herve, additional, Dejoie, Thomas, additional, and Attal, Michel, additional
- Published
- 2015
- Full Text
- View/download PDF
39. Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria.
- Author
-
Fouquet, Guillemette, Snell, Kym IE, Guidez, Stéphanie, Schraen, Susanna, Boyle, Eileen, Renaud, Loïc, Desmier, Déborah, Machet, Antoine, Moya, Niels, Systchenko, Thomas, Gruchet, Cécile, Decaux, Olivier, Arnulf, Bertrand, Fohrer, Cécile, Richez, Valentine, Kolb, Brigitte, Macro, Margaret, Karlin, Lionel, Royer, Bruno, and Pegourie, Brigitte
- Subjects
MULTIPLE myeloma treatment ,IMMUNOASSAY ,IMMUNOGLOBULINS ,MYELOMA proteins ,IMMUNOGLOBULIN idiotypes - Abstract
Automated serum heavy + light chain (HLC) immunoassays can measure the intact immunoglobulins of each light chain type separately. We though to compare HLC assays with electrophoretic techniques in determining International Myeloma Working Group (IMWG) response criteria. 114 myeloma patients from 2 trials were included. HLC measurements were made utilizing archived sera and response assessments compared with those based on electrophoretic analysis at the time of the trials. Assessments at ~90 days and maximal response were compared as was the power of the 2 techniques for predicting later responses, overall survival, and progression. The kappa statistic indicated good agreement between the 2 methods for determining IMWG response criteria, although HLC measurements might give better predictions of subsequent responses and frequently gave an earlier indication of change. HLC measurements could represent an alternative to electrophoretic techniques in determining IMWG response. Validation with a greater range of patient responses is needed for confirmation. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
40. Exome sequencing identifies germline variants in DIS3in familial multiple myeloma
- Author
-
Pertesi, Maroulio, Vallée, Maxime, Wei, Xiaomu, Revuelta, Maria V., Galia, Perrine, Demangel, Delphine, Oliver, Javier, Foll, Matthieu, Chen, Siwei, Perrial, Emeline, Garderet, Laurent, Corre, Jill, Leleu, Xavier, Boyle, Eileen M., Decaux, Olivier, Rodon, Philippe, Kolb, Brigitte, Slama, Borhane, Mineur, Philippe, Voog, Eric, Le Bris, Catherine, Fontan, Jean, Maigre, Michel, Beaumont, Marie, Azais, Isabelle, Sobol, Hagay, Vignon, Marguerite, Royer, Bruno, Perrot, Aurore, Fuzibet, Jean-Gabriel, Dorvaux, Véronique, Anglaret, Bruno, Cony-Makhoul, Pascale, Berthou, Christian, Desquesnes, Florence, Pegourie, Brigitte, Leyvraz, Serge, Mosser, Laurent, Frenkiel, Nicole, Augeul-Meunier, Karine, Leduc, Isabelle, Leyronnas, Cécile, Voillat, Laurent, Casassus, Philippe, Mathiot, Claire, Cheron, Nathalie, Paubelle, Etienne, Moreau, Philippe, Bignon, Yves–Jean, Joly, Bertrand, Bourquard, Pascal, Caillot, Denis, Naman, Hervé, Rigaudeau, Sophie, Marit, Gérald, Macro, Margaret, Lambrecht, Isabelle, Cliquennois, Manuel, Vincent, Laure, Helias, Philippe, Avet-Loiseau, Hervé, Moreno, Victor, Reis, Rui Manuel, Varkonyi, Judit, Kruszewski, Marcin, Vangsted, Annette Juul, Jurczyszyn, Artur, Zaucha, Jan Maciej, Sainz, Juan, Krawczyk-Kulis, Malgorzata, Wątek, Marzena, Pelosini, Matteo, Iskierka-Jażdżewska, Elzbieta, Grząśko, Norbert, Martinez-Lopez, Joaquin, Jerez, Andrés, Campa, Daniele, Buda, Gabriele, Lesueur, Fabienne, Dudziński, Marek, García-Sanz, Ramón, Nagler, Arnon, Rymko, Marcin, Jamroziak, Krzysztof, Butrym, Aleksandra, Canzian, Federico, Obazee, Ofure, Nilsson, Björn, Klein, Robert J., Lipkin, Steven M., McKay, James D., and Dumontet, Charles
- Published
- 2019
- Full Text
- View/download PDF
41. Bortezomib and High-Dose Melphalan Vs. High-Dose Melphalan As Conditioning Regimen before Autologous Stem Cell Transplantation in De Novo Multiple Myeloma Patients: A Phase 3 Study of the Intergroupe Francophone Du Myelome (IFM 2014-02)
- Author
-
Roussel, Murielle, Hebraud, Benjamin, Lauwers-Cances, Valerie, Macro, Margaret, Leleu, Xavier, Hulin, Cyrille, Karlin, Lionel, Royer, Bruno, Perrot, Aurore, Moreau, Philippe, Caillot, Denis, Rigaudeau, Sophie, Dib, Mamoun, Nicolas-Virelizier, Emmanuelle, Escoffre-Barbe, Martine, Belhadj, Karim, Pegourie, Brigitte, Stoppa, Anne-Marie, Araujo, Carla, Doyen, Chantal, Fontan, Jean, Kolb, Brigitte, Garderet, Laurent, Brechignac, Sabine, Malfuson, Jean Valere, Dorvaux, Veronique, Lenain, Pascal, Benbrahim, Omar, Jaccard, Arnaud, Borel, Cecile, Avet Loiseau, Herve, and Attal, Michel
- Published
- 2017
- Full Text
- View/download PDF
42. Impact of Renal Impairment (RI) on Outcomes after Treatment (Tx) with Lenalidomide and Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): First Trial Results
- Author
-
Dimopoulos, Meletios A., primary, Cheung, Matthew C, additional, Roussel, Murielle, additional, Liu, Ting, additional, Gamberi, Barbara, additional, Kolb, Brigitte, additional, Derigs, H. Guenter, additional, Eom, Hyeon Seok, additional, Belhadj, Karim, additional, Lenain, Pascal, additional, van der Jagt, Richard H., additional, Rigaudeau, Sophie, additional, Dib, Mamoun, additional, Hall, Rachel, additional, Jaccard, Arnaud, additional, Tosikyan, Axel, additional, Karlin, Lionel, additional, Bensinger, William, additional, Schots, Rik, additional, Chen, Guang, additional, Marek, Jennifer, additional, Ervin-Haynes, Annette, additional, and Facon, Thierry, additional
- Published
- 2014
- Full Text
- View/download PDF
43. Long-Term Exposure to Pomalidomide-Dexamethasone in Pts with Refractory Myeloma
- Author
-
Pegourie, Brigitte, primary, Petillon, Marie Odile, additional, Karlin, Lionel, additional, Caillot, Denis, additional, Roussel, Murielle, additional, Arnulf, Bertrand, additional, Mathiot, Claire, additional, Marit, Gerald, additional, Macro, Margaret, additional, Kolb, Brigitte, additional, Stoppa, Anne-Marie, additional, Brechiniac, Sabine, additional, Garderet, Laurent, additional, Royer, Bruno, additional, Hulin, Cyril, additional, Benbouker, Lotfi B, additional, Decaux, Olivier, additional, Escoffre-Barbe, Martine, additional, Fermand, Jean Paul, additional, Moreau, Philippe, additional, Avet-Loiseau, Hervé, additional, Attal, Michel, additional, Facon, Thierry, additional, and Leleu, Xavier, additional
- Published
- 2014
- Full Text
- View/download PDF
44. Hevylite® to Monitor Hypogammaglobulinemia, a Predictor of Response to Therapy in Multiple Myeloma
- Author
-
Fouquet, Guillemette, primary, Schraen, Susanna, additional, Faucompré, Jean-Luc, additional, Karlin, Lionel, additional, Macro, Margaret, additional, Hulin, Cyrille, additional, Onraed, Brigitte, additional, Garderet, Laurent, additional, Roussel, Murielle, additional, Arnulf, Bertrand, additional, Pegourie, Brigitte, additional, Kolb, Brigitte, additional, Stoppa, Anne-Marie, additional, Brechiniac, Sabine, additional, Marit, Gerald, additional, Mathiot, Claire, additional, Banos, Anne, additional, Tiab, Mourad, additional, Dib, Mamoun, additional, Fuzibet, Jean-Gabriel, additional, Petillon, Marie Odile, additional, Rodon, Philippe, additional, Wetterwald, Marc, additional, Royer, Bruno, additional, Legros, Laurence, additional, Benboubker, Lotfi, additional, Decaux, Olivier, additional, Caillot, Denis, additional, Escoffre-Barbe, Martine, additional, Fermand, Jean Paul, additional, Moreau, Philippe, additional, Attal, Michel, additional, Avet-Loiseau, Hervé, additional, Facon, Thierry, additional, Leleu, Xavier, additional, and Harding, Stephen, additional
- Published
- 2014
- Full Text
- View/download PDF
45. Hevylite® to Monitor Response to Therapy in Multiple Myeloma
- Author
-
Fouquet, Guillemette, primary, Schraen, Susanna, additional, Faucompré, Jean-Luc, additional, Karlin, Lionel, additional, Macro, Margaret, additional, Hulin, Cyrille, additional, Onraed, Brigitte, additional, Garderet, Laurent, additional, Roussel, Murielle, additional, Arnulf, Bertrand, additional, Pegourie, Brigitte, additional, Kolb, Brigitte, additional, Stoppa, Anne-Marie, additional, Brechignac, Sabine, additional, Michallet, Mauricette, additional, Marit, Gerald, additional, Mathiot, Claire, additional, Banos, Anne, additional, Tiab, Mourad, additional, Dib, Mamoun, additional, Fuzibet, Jean-Gabriel, additional, Petillon, Marie-Odile, additional, Rodon, Philippe, additional, Wetterwald, Marc, additional, Royer, Bruno, additional, Legros, Laurence, additional, Benboubker, Lofti, additional, Decaux, Olivier, additional, Caillot, Denis, additional, Escoffre-Barbe, Martine, additional, Fermand, Jean-Paul, additional, Moreau, Philippe, additional, Attal, Michel, additional, Avet-Loiseau, Hervé, additional, Facon, Thierry, additional, and Leleu, Xavier, additional
- Published
- 2014
- Full Text
- View/download PDF
46. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire
- Author
-
Soussain, Carole, Hoang-Xuan, Khê, Taillandier, Luc, Fourme, Emmanuelle, Choquet, Sylvain, Witz, Francis, Casasnovas, Olivier, Dupriez, Brigitte, Souleau, Bertrand, Taksin, Anne-Laure, Gisselbrecht, Christian, Jaccard, Arnaud, Omuro, Antonio, Sanson, Marc, Janvier, Maud, Kolb, Brigitte, Zini, Jean-Marc, Leblond, Véronique, Renseigné, Non, Biologie des Interactions Neurones / Glie, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de neurologie 1 [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Réseau d'Etude des Gliomes, REG, Service de Neuro-Oncologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service d'hématologie-oncologie adultes, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Physiologie Moléculaire de la Réponse Immune et des Lymphoproliférations (PMRIL), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Centre National de la Recherche Scientifique (CNRS), Service d'Hématologie biologique [CHU Limoges], CHU Limoges, UPMC - Département de neurologie 2 - Mazarin, Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Pitié-Salpêtrière [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
- Subjects
Male ,Oncology ,Cancer Research ,MESH: Combined Modality Therapy ,MESH: Busulfan ,medicine.medical_treatment ,Salvage therapy ,Hematopoietic stem cell transplantation ,MESH: Eye Neoplasms ,0302 clinical medicine ,Antineoplastic Combined Chemotherapy Protocols ,MESH: Cytarabine ,Prospective Studies ,Etoposide ,MESH: Etoposide ,MESH: Aged ,MESH: Middle Aged ,Brain Neoplasms ,MESH: Thiotepa ,Cytarabine ,Hematopoietic Stem Cell Transplantation ,Middle Aged ,Combined Modality Therapy ,3. Good health ,MESH: Salvage Therapy ,Survival Rate ,MESH: Antineoplastic Combined Chemotherapy Protocols ,030220 oncology & carcinogenesis ,MESH: Brain Neoplasms ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,Female ,Lymphoma, Large B-Cell, Diffuse ,Intraocular lymphoma ,Stem cell ,MESH: Neoplasm Recurrence, Local ,medicine.drug ,Adult ,medicine.medical_specialty ,MESH: Survival Rate ,03 medical and health sciences ,Multicenter trial ,Internal medicine ,medicine ,Humans ,Busulfan ,Cyclophosphamide ,MESH: Hematopoietic Stem Cell Transplantation ,Aged ,Salvage Therapy ,Chemotherapy ,MESH: Humans ,business.industry ,Eye Neoplasms ,MESH: Cyclophosphamide ,MESH: Adult ,medicine.disease ,MESH: Male ,MESH: Prospective Studies ,Surgery ,Lymphoma ,MESH: Lymphoma, Large B-Cell, Diffuse ,Methotrexate ,Neoplasm Recurrence, Local ,business ,human activities ,MESH: Female ,Thiotepa ,030217 neurology & neurosurgery - Abstract
Purpose The prognosis of relapsing primary CNS lymphoma (PCNSL) is poor. We report the results of a prospective multicenter trial of intensive chemotherapy followed by autologous hematopoietic stem-cell rescue (IC + HCR) in immunocompetent adult patients with PCNSL or intraocular lymphoma (IOL) after failure of high-dose methotrexate-based treatment. Patients and Methods Salvage treatment consisted of two cycles of high-dose cytarabine and etoposide (CYVE). Intensive chemotherapy combined thiotepa, busulfan, and cyclophosphamide. Forty-three patients (median age, 52 years; range, 23 to 65 years) were included, with relapse (n = 22), refractory disease (n = 17), or a partial response to first-line treatment (n = 4). The response to CYVE was not assessable in three cases because of treatment-related death. Twenty patients (47%) were chemosensitive to CYVE: 15 of them proceeded to IC + HCR. IC + HCR was also administered to 12 patients who did not respond to CYVE. All but one of the 27 patients who underwent IC + HCR entered complete remission. Results With a median follow-up of 36 months, the median overall survival was 18.3 months in the overall population, and 58.6 months among patients who completed IC + HCR. The respective median progression-free survival (PFS) times after IC + HCR were 11.6 and 41.1 months. The 2-year overall survival probability was 45% in the whole population and 69% among the 27 patients who received IC + HCR. The 2-year PFS probability was 43% among all the patients and 58% in the IC + HCR subpopulation. Conclusion IC + HCR is an effective treatment for refractory and recurrent PCNSL.
- Published
- 2008
47. ASXL1 but Not TET2 Mutations Adversely Impact Overall Survival of Patients Suffering Systemic Mastocytosis with Associated Clonal Hematologic Non-Mast-Cell Diseases
- Author
-
Damaj, Gandhi, primary, Joris, Magalie, additional, Chandesris, Olivia, additional, Hanssens, Katia, additional, Soucie, Erinn, additional, Canioni, Danielle, additional, Kolb, Brigitte, additional, Durieu, Isabelle, additional, Gyan, Emanuel, additional, Livideanu, Cristina, additional, Chèze, Stephane, additional, Diouf, Momar, additional, Garidi, Reda, additional, Georgin-Lavialle, Sophie, additional, Asnafi, Vahid, additional, Lhermitte, Ludovic, additional, Lavigne, Christian, additional, Launay, David, additional, Arock, Michel, additional, Lortholary, Olivier, additional, Dubreuil, Patrice, additional, and Hermine, Olivier, additional
- Published
- 2014
- Full Text
- View/download PDF
48. Safety of thalidomide in newly diagnosed elderly myeloma patients:an individual patient data meta-analysis of six randomized trials
- Author
-
Palumbo, Antonio, Waage, Anders, Hulin, Cyrille, Beksac, Meral, Zweegman, Sonja, Gay, Francesca, Gimsing, Peter, Leleu, Xavier, Wijermans, Pierre, Sucak, Gulan, Pezzatti, Sara, Juliusson, Gunnar, Pégourié, Brigitte, Schaafsma, Martijn, Galli, Monica, Turesson, Ingemar, Kolb, Brigitte, van der Holt, Bronno, Baldi, Ileana, Rolke, Jürgen, Ciccone, Giovannino, Wetterwald, Marc, Lokhorst, Henk, Boccadoro, Mario, Rodon, Philippe, Sonneveld, Pieter, Palumbo, Antonio, Waage, Anders, Hulin, Cyrille, Beksac, Meral, Zweegman, Sonja, Gay, Francesca, Gimsing, Peter, Leleu, Xavier, Wijermans, Pierre, Sucak, Gulan, Pezzatti, Sara, Juliusson, Gunnar, Pégourié, Brigitte, Schaafsma, Martijn, Galli, Monica, Turesson, Ingemar, Kolb, Brigitte, van der Holt, Bronno, Baldi, Ileana, Rolke, Jürgen, Ciccone, Giovannino, Wetterwald, Marc, Lokhorst, Henk, Boccadoro, Mario, Rodon, Philippe, and Sonneveld, Pieter
- Abstract
Background. Melphalan-prednisone-thalidomide (MPT) improves outcome in multiple myeloma (MM) patients, and it is now considered a standard of care for patients not eligible for transplantation. However, this treatment is a major source of morbidity. Design and Methods. An individual patient data meta-analysis (N=1680) of all the six randomized trials comparing MPT vs melphalan-prednisone (MP) was performed. The main objective was to estimate the risk of serious adverse events (AEs) and their impact on outcome. The primary endpoints were the 2-year cumulative incidence of grade 3-4 hematologic and non-hematologic AEs. Results. At least 75% of the grade 3-4 AEs occurred during the first six months of treatment in both MPT and MP groups. A higher cumulative incidence of grade 3-4 hematologic (28% vs 22%, HR 1.32, 95%CI 1.05-1.66) and non-hematologic (39% vs 17%, HR 2.78, 95%CI 2.21-3.50) AEs was documented in patients treated with MPT vs MP. Grade 3-4 non-hematologic AEs were significantly increased in patients with poor performance status. Occurrence of grade 3-4 non-hematologic AEs negatively impacted on progression-free survival (PFS) (HR 1.24, 95%CI 1.07-1.45) and overall survival (OS), (HR 1.23, 95%CI 1.03-1.47). In addition to the occurrence of AEs, PFS and OS were also negatively affected by advanced ISS stage, high creatinine levels and poor performance status. Age had a negative impact on OS as well. Conclusions. Although MPT improved outcome, it increased the incidence of toxicities, especially non-hematologic. Serious non-hematologic AEs, older age, poor performance status, and high creatinine levels have a negative impact on survival.
- Published
- 2013
49. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation
- Author
-
UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Garderet, Laurent, Iacobelli, Simona, Moreau, Philippe, Dib, Mamoun, Lafon, Ingrid, Niederwieser, Dietger, Masszi, Tamas, Fontan, Jean, Michallet, Mauricette, Gratwohl, Alois, Milone, Giuseppe, Doyen, Chantal, Pegourie, Brigitte, Hajek, Roman, Casassus, Philippe, Kolb, Brigitte, Chaleteix, Carine, Hertenstein, Bernd, Onida, Francesco, Ludwig, Heinz, Ketterer, Nicolas, Koenecke, Christian, van Os, Marleen, Mohty, Mohamad, Cakana, Andrew, Gorin, Norbert Claude, de Witte, Theo, Harousseau, Jean Luc, Morris, Curly, Gahrton, Gösta, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Garderet, Laurent, Iacobelli, Simona, Moreau, Philippe, Dib, Mamoun, Lafon, Ingrid, Niederwieser, Dietger, Masszi, Tamas, Fontan, Jean, Michallet, Mauricette, Gratwohl, Alois, Milone, Giuseppe, Doyen, Chantal, Pegourie, Brigitte, Hajek, Roman, Casassus, Philippe, Kolb, Brigitte, Chaleteix, Carine, Hertenstein, Bernd, Onida, Francesco, Ludwig, Heinz, Ketterer, Nicolas, Koenecke, Christian, van Os, Marleen, Mohty, Mohamad, Cakana, Andrew, Gorin, Norbert Claude, de Witte, Theo, Harousseau, Jean Luc, Morris, Curly, and Gahrton, Gösta
- Abstract
PURPOSE: This prospective multicenter phase III study compared the efficacy and safety of a triple combination (bortezomib-thalidomide-dexamethasone [VTD]) versus a dual combination (thalidomide-dexamethasone [TD]) in patients with multiple myeloma (MM) progressing or relapsing after autologous stem-cell transplantation (ASCT). PATIENTS AND METHODS: Overall, 269 patients were randomly assigned to receive bortezomib (1.3 mg/m(2) intravenous bolus) or no bortezomib for 1 year, in combination with thalidomide (200 mg per day orally) and dexamethasone (40 mg orally once a day on 4 days once every 3 weeks). Bortezomib was administered on days 1, 4, 8, and 11 with a 10-day rest period (day 12 to day 21) for eight cycles (6 months), and then on days 1, 8, 15, and 22 with a 20-day rest period (day 23 to day 42) for four cycles (6 months). RESULTS: Median time to progression (primary end point) was significantly longer with VTD than TD (19.5 v 13.8 months; hazard ratio, 0.59; 95% CI, 0.44 to 0.80; P = .001), the complete response plus near-complete response rate was higher (45% v 25%; P = .001), and the median duration of response was longer (17.2 v 13.4 months; P = .03). The 24-month survival rate was in favor of VTD (71% v 65%; P = .093). Grade 3 peripheral neuropathy was more frequent with VTD (29% v 12%; P = .001) as were the rates of grades 3 and 4 infection and thrombocytopenia. CONCLUSION: VTD was more effective than TD in the treatment of patients with MM with progressive or relapsing disease post-ASCT but was associated with a higher incidence of grade 3 neurotoxicity.
- Published
- 2012
50. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial.
- Author
-
UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Moreau, Philippe, Attal, Michel, Pégourié, Brigitte, Planche, Lucie, Hulin, Cyrille, Facon, Thierry, Stoppa, Anne-Marie, Fuzibet, Jean-Gabriel, Grosbois, Bernard, Doyen, Chantal, Ketterer, Nicolas, Sebban, Catherine, Kolb, Brigitte, Chaleteix, Carine, Dib, Mamoun, Voillat, Laurent, Fontan, Jean, Garderet, Laurent, Jaubert, Jérôme, Mathiot, Claire, Esseltine, Dixie, Avet-Loiseau, Hervé, Harousseau, Jean-Luc, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Moreau, Philippe, Attal, Michel, Pégourié, Brigitte, Planche, Lucie, Hulin, Cyrille, Facon, Thierry, Stoppa, Anne-Marie, Fuzibet, Jean-Gabriel, Grosbois, Bernard, Doyen, Chantal, Ketterer, Nicolas, Sebban, Catherine, Kolb, Brigitte, Chaleteix, Carine, Dib, Mamoun, Voillat, Laurent, Fontan, Jean, Garderet, Laurent, Jaubert, Jérôme, Mathiot, Claire, Esseltine, Dixie, Avet-Loiseau, Hervé, and Harousseau, Jean-Luc
- Abstract
In the 2005-01 trial, we have demonstrated that bortezomib-dexamethasone as induction therapy before autologous stem cell transplantation was superior to vincristine-adriamycin-dexamethasone. We conducted a post-hoc analysis to assess the prognostic impact of initial characteristics as well as response to therapy in patients enrolled in this study. Multivariate analysis showed that ISS stages 2 and 3 and achievement of response less than very good partial response (VGPR) both after induction therapy and after autologous stem cell transplantation were adverse prognostic factors for progression-free survival, the most important one being achievement of response less than VGPR after induction. Progression-free survival was significantly improved with bortezomib-dexamethasone induction therapy in patients with poor-risk cytogenetics and ISS stages 2 and 3 compared with vincristine-adriamycin-dexamethasone. In these 2 groups of patients, achievement of at least VGPR after induction was of major importance. This study is registered with EudraCT (https://eudract.ema.europa.eu; EUDRACT 2005-000537-38) and http://clinicaltrials.gov (NCT00200681).
- Published
- 2011
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.